363 related articles for article (PubMed ID: 24718924)
1. The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review).
Nakanishi A; Kitagishi Y; Ogura Y; Matsuda S
Int J Oncol; 2014 Jun; 44(6):1813-9. PubMed ID: 24718924
[TBL] [Abstract][Full Text] [Related]
2. Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN.
Blanco A; Graña B; Fachal L; Santamariña M; Cameselle-Teijeiro J; Ruíz-Ponte C; Carracedo A; Vega A
Clin Genet; 2010 Feb; 77(2):193-6. PubMed ID: 19930417
[No Abstract] [Full Text] [Related]
3. PTEN autoregulates its expression by stabilization of p53 in a phosphatase-independent manner.
Tang Y; Eng C
Cancer Res; 2006 Jan; 66(2):736-42. PubMed ID: 16424003
[TBL] [Abstract][Full Text] [Related]
4. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.
Bennett KL; Mester J; Eng C
JAMA; 2010 Dec; 304(24):2724-31. PubMed ID: 21177507
[TBL] [Abstract][Full Text] [Related]
5. Naturally occurring germline and tumor-associated mutations within the ATP-binding motifs of PTEN lead to oxidative damage of DNA associated with decreased nuclear p53.
He X; Ni Y; Wang Y; Romigh T; Eng C
Hum Mol Genet; 2011 Jan; 20(1):80-9. PubMed ID: 20926450
[TBL] [Abstract][Full Text] [Related]
6. Esophageal cancer in a family with hamartomatous tumors and germline PTEN frameshift and SMAD7 missense mutations.
Sherman SK; Maxwell JE; Qian Q; Bellizzi AM; Braun TA; Iannettoni MD; Darbro BW; Howe JR
Cancer Genet; 2015; 208(1-2):41-6. PubMed ID: 25554686
[TBL] [Abstract][Full Text] [Related]
7. The p53 mutation "gradient effect" and its clinical implications.
Zambetti GP
J Cell Physiol; 2007 Nov; 213(2):370-3. PubMed ID: 17671971
[TBL] [Abstract][Full Text] [Related]
8. PTEN, more than the AKT pathway.
Blanco-Aparicio C; Renner O; Leal JF; Carnero A
Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
[TBL] [Abstract][Full Text] [Related]
9. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
[TBL] [Abstract][Full Text] [Related]
10. [Familial breast cancer, ovarian cancer].
Inoue M
Nihon Rinsho; 2006 Jun; Suppl 2():366-70. PubMed ID: 16817423
[No Abstract] [Full Text] [Related]
11. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.
Gu J; Kawai H; Wiederschain D; Yuan ZM
Cancer Res; 2001 Feb; 61(4):1741-6. PubMed ID: 11245491
[TBL] [Abstract][Full Text] [Related]
12. Shaping genetic alterations in human cancer: the p53 mutation paradigm.
Soussi T; Wiman KG
Cancer Cell; 2007 Oct; 12(4):303-12. PubMed ID: 17936556
[TBL] [Abstract][Full Text] [Related]
13. p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome.
Debelenko LV; Perez-Atayde AR; Dubois SG; Grier HE; Pai SY; Shamberger RC; Kozakewich HP
Pediatr Dev Pathol; 2010; 13(3):218-24. PubMed ID: 20028212
[TBL] [Abstract][Full Text] [Related]
14. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members.
Lomax ME; Barnes DM; Hupp TR; Picksley SM; Camplejohn RS
Oncogene; 1998 Aug; 17(5):643-9. PubMed ID: 9704930
[TBL] [Abstract][Full Text] [Related]
15. Translational advances regarding hereditary breast cancer syndromes.
Gage M; Wattendorf D; Henry LR
J Surg Oncol; 2012 Apr; 105(5):444-51. PubMed ID: 22441895
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer.
Agrawal S; Eng C
Hum Mol Genet; 2006 Mar; 15(5):777-87. PubMed ID: 16436456
[TBL] [Abstract][Full Text] [Related]
17. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Choi HJ; Chung TW; Kang SK; Lee YC; Ko JH; Kim JG; Kim CH
Glycobiology; 2006 Jul; 16(7):573-83. PubMed ID: 16574813
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.
Rodríguez-Escudero I; Oliver MD; Andrés-Pons A; Molina M; Cid VJ; Pulido R
Hum Mol Genet; 2011 Nov; 20(21):4132-42. PubMed ID: 21828076
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel PTEN intronic deletion in Li-Fraumeni syndrome and its effect on RNA processing.
Brown LT; Sexsmith E; Malkin D
Cancer Genet Cytogenet; 2000 Nov; 123(1):65-8. PubMed ID: 11120338
[TBL] [Abstract][Full Text] [Related]
20. A novel mutation of the PTEN gene in a Japanese patient with Cowden syndrome and bilateral breast cancer.
Tate G; Suzuki T; Endo Y; Mitsuya T
Cancer Genet Cytogenet; 2008 Jul; 184(1):67-71. PubMed ID: 18558293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
